tumor-infiltrating lymphocytes + chimeric antigen receptor tumor-infiltrating lymphocytes

A combination cellular immunotherapy approach that utilizes both tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor-modified tumor-infiltrating lymphocytes (CAR-TILs). TIL therapy uses T cells harvested directly from a patient's tumor that are expanded in the laboratory and reinfused to target cancer cells. CAR-TILs are TILs that have been genetically modified to express chimeric antigen receptors that recognize specific tumor antigens. This combination approach leverages the natural tumor-infiltrating ability of TILs with the enhanced targeting specificity of CAR technology, potentially overcoming limitations of both standard TIL therapy and traditional CAR-T cell therapy, particularly for solid tumors.

Other names

TILs + CAR-TILs